摘要
原发性肝癌是一种在全球范围内发病率和死亡率持续上升的恶性肿瘤,给患者和社会带来了沉重的负担,其中肝细胞癌是原发性肝癌中的常见类型。放射治疗作为肝细胞癌的重要治疗手段之一,能够有效控制肿瘤的局部生长并缓解患者症状。然而,放疗抵抗问题严重影响了治疗效果,成为临床治疗中的一大挑战。当前研究表明,肝细胞癌放疗抵抗的机制较为复杂,涉及细胞内信号通路异常激活、肿瘤微环境变化以及基因表达调控等多种因素。因此,临床上提出一系列针对放疗抵抗的应对策略,包括调控细胞信号通路、改善肿瘤微环境、联合治疗等,这些策略展现出良好的应用前景。本文旨在综述放疗抵抗的相关机制及应对策略的研究进展,以期为肝细胞癌放疗研究提供新的视角。
Primary liver cancer is a malignant tumor with continuously rising incidence and mortality rates worldwide,imposing a heavy burden on patients and society,and hepatocellular carcinoma(HCC)is a common type of primary liver cancer.As one of the important treatment methods for HCC,radiotherapy can effectively control the local growth of tumors and alleviate symptoms in patients.However,radiotherapy resistance seriously affects the treatment effect and has become a major challenge in clinical treatment.Current research shows a complex mechanism of radiotherapy resistance in HCC,involving multiple factors such as abnormal activation of intracellular signaling pathways,changes in tumor microenvironment,and regulation of gene expression.Therefore,a series of strategies have been proposed to address radiotherapy resistance in clinical practice,including regulating cell signaling pathways,improving tumor microenvironment,and combining different treatment modalities,and such strategies have shown promising application prospects.This article reviews the research advances in the mechanism of radiotherapy resistance and related coping strategies,in order to provide new perspectives for future research on radiotherapy for HCC.
作者
王钦波
李术华
孙航
吴传新
WANG Qinbo;LI Shuhua;SUN Hang;WU Chuanxin(Department of Hepatobiliary Surgery,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China;Institute of Infection and Hepatology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
出处
《临床肝胆病杂志》
北大核心
2025年第10期2154-2160,共7页
Journal of Clinical Hepatology
基金
重庆市自然科学基金杰出青年项目(CSTB2022NSCQ-JQX0032)
重庆医科大学未来医学青年创新团队支持计划(W0156)。
关键词
癌
肝细胞
放疗抵抗
治疗学
Carcinoma,Hepatocellular
Radiotherapy Resistance
Therapeutics
